The review focused on evidence from the United States; global evidence was included for identified evidence gaps.<h4>Results</h4>The median rate of primary <i>MET</i>amp in NSCLC across the references was 4.8% (n=4 studies) and of secondary <i>MET</i>amp (epidermal growth factor receptor [<i>EGFR</i>]-mutant NSCLC) was 15% (n=10). This evidence concerns the gene EGFR and non-small cell lung carcinoma.